Burdorf Alex, Järvholm Bengt, Englund Anders
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.
Int J Cancer. 2005 Jan 10;113(2):298-301. doi: 10.1002/ijc.20552.
In recent years in several countries a deceleration or leveling off of pleural mesothelioma rates has been observed. The impact of asbestos used was analysed by comparing a country with a relative modest incidence rate of mesothelioma (Sweden) and an early response to asbestos use with a country with one of the highest incidence rates of mesothelioma in Western Europe (The Netherlands). In Sweden the Cancer Register provided information on the annual incidence of pleural mesothelioma, whereas in The Netherlands mortality data were provided by Statistics Netherlands for the period 1969-2001. In The Netherlands among men the incidence rate was consistently higher (1.5-2 times) than in Sweden, whereas among women similar rates were observed. Assuming that none of the female cases was caused by occupational exposure to asbestos, minimum estimates of the etiologic fraction for occupational exposure to asbestos in men would be 82% in Sweden and 92% in The Netherlands. Possible explanations for the consistently higher incidence rates in the Netherlands than in Sweden include differences in exposure levels, the proportion of exposed subjects in the workforce and types of asbestos fibres used. Measures to decrease the exposure to asbestos seem to have decreased the risk of pleural mesothelioma in both countries among age groups below 60 years. This effect will result in a leveling off of the increase in pleural mesothelioma in both countries in the next decade.
近年来,在一些国家已观察到胸膜间皮瘤发病率出现减速或趋于平稳的情况。通过将一个间皮瘤发病率相对适中的国家(瑞典)以及对石棉使用的早期反应情况,与西欧间皮瘤发病率最高的国家之一(荷兰)进行比较,分析了所使用石棉的影响。在瑞典,癌症登记处提供了胸膜间皮瘤的年度发病率信息,而在荷兰,荷兰统计局提供了1969 - 2001年期间的死亡率数据。在荷兰,男性的发病率一直高于瑞典(1.5至2倍),而女性的发病率则相近。假设女性病例均非职业性接触石棉所致,那么在瑞典男性中职业性接触石棉的病因分数最低估计为82%,在荷兰为92%。荷兰发病率持续高于瑞典的可能解释包括接触水平差异、劳动力中接触石棉的人群比例以及所使用石棉纤维的类型。减少石棉接触的措施似乎已降低了两国60岁以下年龄组患胸膜间皮瘤的风险。这种影响将导致两国在未来十年胸膜间皮瘤发病率增长趋于平稳。